Ligufalimab

莱法利单抗

Report date: 2026/05/21 20:00:22

Base Information

Drug NameLigufalimab
Drug Alias NameAK-117
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesSmall Cell Lung Carcinoma +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaFrance +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesZhongshan Akeso Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAkeso Pharmaceuticals IncKangfang Biotechnology (Cayman) Co LtdUniversity of Texas Southwestern Medical Center +[8] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesSmall Cell Lung Carcinoma +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank